Phase 2 N=4 Mexiletine for Muscle Cramps in Charcot Marie Tooth Disease
Charcot Marie Tooth Disease
Primary: Number of Participants With a Decrease in Cramp Duration — 2; 0 participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=40 Beneficial Effects of Magnesium Supplementation On Idiopathic Muscle Cramps
Muscle Cramp
Primary: Change in Frequency of Leg Cramps — .99; .53 Cramps per week
Phase 4 N=23 Mexiletine for the Treatment of Muscle Cramps in ALS
Muscle Cramps in Amyotrophic Lateral Sclerosis
Primary: Daily Muscle Cramps — 6.1; 4.7; 4.9; 2.5 Cramps per 24 hours
Phase 4 N=30 Ropinirole for the Treatment of Muscle Cramps in Patients With Cirrhosis
Muscle Cramp · Cirrhosis
Primary: Frequency of Muscle Cramps as Assessed by Patient Survey — 1.14; 1.23 score on a scale
N/A N=57 Effect of Theraworx/[pH]Uel on Night-time Leg Cramps and Spasm Symptoms
Leg Cramp, Nocturnal
Primary: Change in Restless Legs Syndrome Quality of Life Instrument (RLSQoL) Over 4 Weeks — 78.92; 80.75; 77.75; 83.16 units on a scale
Phase 2 N=11 TJ-68 Clinical Trial in Patients With Amyotrophic Lateral Sclerosis (ALS) and Muscle Cramps
Amyotrophic Lateral Sclerosis · Muscle Cramp
Primary: Visual Analog Scale (MCS-VAS) Score — 2.07; 1.7 score on a scale
Phase 2 N=10 Safety and Efficacy of Baclofen for Treatment of Muscle Spasms in Patients With Cirrhosis: A Pilot Study
Muscle Cramps · Cirrhosis
Primary: Number of Participants With Adverse Events as a Measure of Safety and Tolerability (Headache) — 3 participants
Phase 2 N=13 Creatine Use and Muscle Stretching in Peripheral Artery Disease
Peripheral Arterial Disease
Primary: Walking Distance — 375; 411; 405; 425 meters — p=0.38
Phase 3 N=39 Clinical Trial of CoQ10 for Mild-to-Moderate Statin-Associated Muscle Symptoms
Pain · Weakness · Cramps
Primary: Percentage of Participants With Reduction in Muscle Pain Associated With Statin Use — 53; 65 % of participants with pain reduction
Phase 2 N=244 Musculoskeletal Effects of Bicarbonate
Muscle Loss · Fractures · Osteoporosis, Age Related
Primary: The Dose of Potassium Bicarbonate Needed for Maximal Suppression of 24-hr Urinary N-telopeptide — 240; 230; 241; -53 nmol/day
N/A N=8 7 Tesla MRI Study in Patients With Statin Related Muscle Complaints
Statin-related Muscle Pain · Muscle Aches · Muscle Weakness
Primary: Change in Pre- and Post-phosphocreatine Relaxation Time — 5.58; 5.083 milliseconds
N/A N=12 Electrical Stimulation of the Muscle Pumps of the Leg
Haemodynamic Physiology
Primary: Venous Haemodynamic Measurements (Volume Flow Rate) — 119; 158; 158; 144 ml/min — p=<0.05
Phase 4 N=38 Study of Arm and Putter Movement in Golfers With Golfer's Cramp
Occupational; Cramp(s)
Primary: Mean Dynamic Change of Rotation at Impact — -38.4; -32.5; -36.5; NA degrees/sec
Phase 3 N=300 The Effect of Pretreatment With Roc on Succinylcholine Myalgias
Myalgia
Primary: Myalgias Perceived at 3 Hours — 81; 83; 83; 15 Participants
N/A N=37 Forearm Immobilization, Metabolic Health, and Muscle Loss
Healthy
Primary: Percent Change in Forearm Glucose Uptake — -73; 127; -95 Percent change in clamp FGU with immob
Phase 4 N=10 Examining the Effect of Burosumab on Muscle Function
X-linked Hypophosphatemia
Primary: Skeletal Muscle Adenosine Triphosphate (ATP) Synthesis Rate — 9.41 umol/g/min — p=0.4147
Phase 3 N=205 Topical Ibuprofen for Delayed Onset Mulscle Soreness
Pain
Primary: Change From Baseline in the Time-Weighted Sum of Muscle Soreness With Movement Over 0-24 Hours Post-Dose 1 (MSM 0-24 ) — 22.2; 17.8; 29.7 units on a scale — p=0.200